How does fitusiran actually stop bleeding in hemophilia?
Fitusiran is an RNA therapy that silences the gene making antithrombin, a natural clot-blocker in your blood. By lowering antithrombin 20–60%, your blood clots better and bleeding episodes drop 94% [1][3].
In the ATLAS-A/B trial, hemophilia patients on fitusiran had 94% fewer bleeding episodes than those on older factor-replacement therapy over 24 weeks. The drug works by targeting messenger RNA (mRNA) that tells your liver to make antithrombin, a protein that naturally stops clots from forming. Once fitusiran binds to that mRNA, your body breaks it down, and antithrombin levels fall to a safe therapeutic range [3].
Your blood has two opposing forces: clotting factors that form clots, and natural blockers like antithrombin that dissolve them. In hemophilia, you lack clotting factors, so clots form slowly or not at all. Fitusiran tips the balance by reducing the blocker, letting your remaining clotting factors work harder and faster to seal wounds and prevent internal bleeds [6].
Steady-state therapeutic effect takes 4–6 weeks because fitusiran must accumulate in your liver cells and suppress antithrombin production gradually. Your doctor monitors antithrombin levels every 4–6 weeks to keep them in the 20–60% range—too low risks clotting, too high loses the bleeding-prevention benefit [2][9].
Ask your hemophilia doctor to show you your antithrombin level trend on a chart during each visit. If it's creeping below 20% or above 60%, a small dose adjustment now prevents a crisis later.